166 related articles for article (PubMed ID: 27340524)
1. Recombinant Human Bone Morphogenetic Protein-2 in Posterolateral Spinal Fusion: What's the Right Dose?
Hoffmann MF; Jones CB; Sietsema DL
Asian Spine J; 2016 Jun; 10(3):457-64. PubMed ID: 27340524
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly.
Hoffmann MF; Jones CB; Sietsema DL
J Orthop Surg Res; 2013 Jan; 8():1. PubMed ID: 23317417
[TBL] [Abstract][Full Text] [Related]
3. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
4. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate.
Boden SD; Martin GJ; Morone MA; Ugbo JL; Moskovitz PA
Spine (Phila Pa 1976); 1999 Jun; 24(12):1179-85. PubMed ID: 10382242
[TBL] [Abstract][Full Text] [Related]
5. Posterolateral lumbar spine fusion with INFUSE bone graft.
Glassman SD; Carreon L; Djurasovic M; Campbell MJ; Puno RM; Johnson JR; Dimar JR
Spine J; 2007; 7(1):44-9. PubMed ID: 17197332
[TBL] [Abstract][Full Text] [Related]
6. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
[TBL] [Abstract][Full Text] [Related]
7. Early-term and mid-term histologic events during single-level posterolateral intertransverse process fusion with rhBMP-2/collagen carrier and a ceramic bulking agent in a nonhuman primate model: implications for bone graft preparation.
Khan SN; Toth JM; Gupta K; Glassman SD; Gupta MC
J Spinal Disord Tech; 2014 Jun; 27(4):212-9. PubMed ID: 23073151
[TBL] [Abstract][Full Text] [Related]
8. rhBMP-2 enhancement of posterolateral spinal fusion in a rabbit model in the presence of concurrently administered doxorubicin.
Singh K; Smucker JD; Ugbo JL; Tortolani PJ; Tsai L; Fei Q; Kuh S; Rumi M; Heller JG; Boden SD; Yoon ST
Spine J; 2007; 7(3):326-31. PubMed ID: 17482116
[TBL] [Abstract][Full Text] [Related]
9. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
[TBL] [Abstract][Full Text] [Related]
10. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
[TBL] [Abstract][Full Text] [Related]
11. Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2.
Itoh H; Ebara S; Kamimura M; Tateiwa Y; Kinoshita T; Yuzawa Y; Takaoka K
Spine (Phila Pa 1976); 1999 Jul; 24(14):1402-5. PubMed ID: 10423783
[TBL] [Abstract][Full Text] [Related]
12. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
13. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion.
Akamaru T; Suh D; Boden SD; Kim HS; Minamide A; Louis-Ugbo J
Spine (Phila Pa 1976); 2003 Mar; 28(5):429-34. PubMed ID: 12616152
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Cost, and Complications of Demineralized Bone Matrix in Instrumented Lumbar Fusion: Comparison With rhBMP-2.
Eleswarapu A; Rowan FA; Le H; Wick JB; Roberto RF; Javidan Y; Klineberg EO
Global Spine J; 2021 Oct; 11(8):1223-1229. PubMed ID: 32748702
[TBL] [Abstract][Full Text] [Related]
15. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
16. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
[TBL] [Abstract][Full Text] [Related]
17. Heterotopic ossification following single-level anterior cervical discectomy and fusion: results from the prospective, multicenter, historically controlled trial comparing allograft to an optimized dose of rhBMP-2.
Arnold PM; Anderson KK; Selim A; Dryer RF; Kenneth Burkus J
J Neurosurg Spine; 2016 Sep; 25(3):292-302. PubMed ID: 27129045
[TBL] [Abstract][Full Text] [Related]
18. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
Glassman SD; Gum JL; Crawford CH; Shields CB; Carreon LY
Spine J; 2011 Jun; 11(6):522-6. PubMed ID: 20598649
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant human bone morphogenetic protein-2 with local bone graft instead of iliac crest bone graft in posterolateral lumbar spine arthrodesis.
Park DK; Kim SS; Thakur N; Boden SD
Spine (Phila Pa 1976); 2013 May; 38(12):E738-47. PubMed ID: 23474598
[TBL] [Abstract][Full Text] [Related]
20. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion.
Glassman SD; Dimar JR; Carreon LY; Campbell MJ; Puno RM; Johnson JR
Spine (Phila Pa 1976); 2005 Aug; 30(15):1694-8. PubMed ID: 16094268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
